Companies › Nanjing Minova Pharmaceutical
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Psychiatry, Other; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MI078 capsule | – | Phase 3 | Postpartum Depression (PPD) | Dec 2027 |
| MI226 injection | – | Phase 1 | Abdominal Fat | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07749742 | MI226 injection | Phase 1 | Abdominal Fat | Other | Feb 2027 |
| NCT07721961 | MI078 capsule | Phase 3 | Postpartum Depression (PPD) | Psychiatry | Dec 2027 |
No annotated target.
–
Adneuris Therapeutics Syndeio Biosciences Vigonvita Life Sciences Clear Scientific Harmony Biosciences Management
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.